This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Immuno-oncology company Neon Therapeutics raises $70mm in Series B financing; later adds $36mm more
07 Dec 2017
Neon Therapeutics raised $70mm in its Series B financing round led by Partner Fund Management. Returning backers Third Rock Ventures and Access Industries joined new investors Fidelity Management & Research, Wellington Management Company, Inbio Ventures, and Nextech Invest. The company will use the funds toward its lead program NEOPV01, a fully personalized neoantigen vaccine, currently in Phase Ib trials; for preclinical development of NEOPTC01, a personalized adoptive T-cell program; and for the Shared Neoantigen Program. Neon has raised $125mm to date through its A and B rounds.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?